Viridian Therapeutics price target lowered to $25 from $29 at B. Riley

B. Riley lowered the firm’s price target on Viridian Therapeutics (VRDN) to $25 from $29 and keeps a Buy rating on the shares. Viridian competitor Acelyrin (SLRN) reported preliminary proof-of-concept data for its insulin like growth factor 1 receptor, lonigutamab, though the sample size is too small to draw definitive conclusions regarding the superiority or inferiority of lonigutamab over competing assets, the analyst tells investors in a research note. The firm anticipates Viridian’s upcoming pivotal studies will successfully meet key endpoints.